Effectiveness and Safety of Firmagon in Androgen Ablative Therapy of Advanced Hormone-Dependent Prostate Carcinoma.

Next Previous
Trial Profile

Effectiveness and Safety of Firmagon in Androgen Ablative Therapy of Advanced Hormone-Dependent Prostate Carcinoma.

Completed
Phase of Trial: Phase IV

Latest Information Update: 14 May 2014

At a glance

  • Drugs Degarelix (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Acronyms FAST
  • Sponsors Ferring Pharmaceuticals

    • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 25 Mar 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 21 Aug 2012 New source identified and integrated (German Clinical Trials Register; DRKS00004051).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top